Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...